← Back to Analyst Consensus 
ADRX N/A
ADARx Pharmaceuticals, Inc.
Current Price —
Implied Upside —
Analysts 0
30-Day Momentum
▲ 4 upgrades / ▼ 0 downgrades / 0 reiterations from 4 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 20, 2026 | TD Cowen | initiate | — → Buy | — | 54% |
| Oct 20, 2026 | JP Morgan | initiate | — → Overweight | — | 55% |
| Oct 20, 2026 | UBS | initiate | — → Buy | — | 54% |
| Oct 20, 2026 | Morgan Stanley | initiate | — → Overweight | — | 54% |
Price Target Trend
Oct 21, 2026 Oct 26, 2026
EPS Estimates
0y —
+1y —
0q —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days